Innate Pharma (IPHA) Non Operating Income (2020 - 2022)
Innate Pharma posted quarterly Non Operating Income of -$557.06 for Q4 2022, up 99.98% on a QoQ basis from -$2.3 million in Q2 2022.
Innate Pharma (IPHA) has 2 years of Non Operating Income data on file, last reported at -$557.06 in Q4 2022.
- For the quarter ending Q4 2022, Non Operating Income changed N/A year-over-year to -$557.06; the trailing twelve-month figure through Dec 2022 stood at -$6.7 million (changed N/A YoY), and the FY2025 full-year result was $5.6 million, up 150.12% from the prior year.
- Non Operating Income for Q4 2022 stood at -$557.06, up from -$2.3 million in the prior quarter.
- Across five years, Non Operating Income topped out at -$557.06 in Q4 2022 and bottomed at -$2.3 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 201.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -557.06 |
| Jun 30, 2022 | -2.26 Mn |
| Dec 31, 2020 | -2.27 Mn |
| Jun 30, 2020 | -2.19 Mn |